Table 1. Baseline Characteristics of Study Population (n = 107).
| Age, y, median (range) | 54 (34-76) |
| Males, n (%) | 75 (70.9) |
| Diabetes, n (%) | 7/103 (6.8) |
| BMI, kg/m2, median (range) | 25.6 (17.1 - 40.1) |
| ASA score ≥3, n (%) | 85/103 (82.5) |
| Nontumoral liver pathology, n (%) | |
| None | 77/95 (81.1) |
| Steatosis >30% or | 6/99 (6.1) |
| steatohepatitis* | |
| Fibrosis (F1-4)† | 8/101 (7.9) |
| Cirrhosis (F5-6)† | 0/101 (0) |
| Sinusoidal injury‡ | 8/96 (8.3) |
| Type of PVE, n (%)§ | |
| RPVE | 40/107 (37.4) |
| RPVE extended to segment IV | 67/107 (62.6) |
| 5-FU or capecitabine based preoperative chemotherapy, n (%) | |
| Any | 96/104 (92.3) |
| >12 wk duration | 46/104 (44.2) |
| Oxaliplatin§ | 83/104 (79.8) |
| Irinotecan§ | 16/104 (15.4) |
| Bevacizumab | 72/104 (69.2) |
| Cetuximab or Panitumumab | 3/104 (2.9) |
When 2 numbers are listed, the numerator is the number of patients with the characteristic and the denominator is the number of patients for whom information about this characteristic was available. Values in parentheses are percentage unless indicated otherwise.
*
Kleiner score 4 or greater.[31]
†
Fibrosis score according to Ishak et al.[32]
‡
Rubbia-Brandt score 2-3 (moderate to severe).[33]
§
Three patients had history of both FOLFOX and FOLFIRI.
BMI, body mass index; ASA, American Society of Anesthesiology; RPVE, right portal vein embolization.